Your session is about to expire
← Back to Search
Durvalumab + Pomalidomide +/- Dexamethasone for Multiple Myeloma
Study Summary
This trial is studying a combination of drugs as a possible treatment for multiple myeloma. A partial clinical hold has been placed on the trial by the FDA based on data related to risks of one of the drugs in the combination in patients with multiple myeloma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 80 Patients • NCT03015129Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I received treatment for myeloma less than 2 weeks ago.My last cancer treatment did not work.I have been treated with lenalidomide and a proteasome inhibitor for my myeloma.I have taken pomalidomide before and my disease did not improve.You have had a severe allergic reaction to thalidomide, lenalidomide, POM, or dex.I have moderate to severe numbness, tingling, or pain in my hands or feet.I've been cancer-free for over 5 years, except for certain skin or early-stage cancers.I can take care of myself and perform daily activities.I have a type of cancer called EMP that can be measured on scans and is possible to biopsy.My multiple myeloma does not produce high levels of M-protein.You are currently smoking cigarettes.I have not had a live vaccine in the last 30 days.I have a serious heart condition.I am not pregnant, nursing, breastfeeding, nor planning to become pregnant during the study.I have been diagnosed with active multiple myeloma and it can be measured.I have complications like blood clots or multiple myeloma affecting my brain or lungs.I have another cancer besides skin or treated cervical cancer that is getting worse or needs treatment.I have been treated with specific immune system targeting drugs before.I've been treated with a monoclonal antibody recently.I had a severe rash from thalidomide, lenalidomide, or pomalidomide.I am positive for HIV or hepatitis A, B, or C.I have had an organ or bone marrow transplant.My myeloma was stable after treatment before it worsened.I have received at least 2 different treatments for my myeloma.
- Group 1: Durvalumab monotherapy
- Group 2: Durvalumab + pomalidomide (POM)
- Group 3: Durvalumab + pomalidomide (POM) + dexamethasone (dex)
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 60 Other Conditions - This treatment demonstrated efficacy for 60 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research endeavor actively seeking to enroll participants?
"According to clinicaltrials.gov, this medical trial is no longer recruiting patients as it was last updated on August 4th 2021. Despite the inactivity of this particular study, there are over 1708 other trials that require participants at present."
What is the geographical scope of this medical trial?
"Patients can participate in this medical trial at a range of sites, including Hackensack University Medical Center (Hackensack), Johns Hopkins Oncology Center (Baltimore) and Cleveland Clinic (Cleveland). There are 13 recruitment centres total."
What medical issues has Durvalumab been known to address?
"Durvalumab is often prescribed for the treatment of ophthalmia and sympathetic conditions. Moreover, it has also been used to ameliorate branch retinal vein occlusion, macular edema, as well as communicable diseases."
Have any additional experiments been conducted related to the use of Durvalumab?
"Durvalumab was first researched in 2002 by the Manitoba Blood & Marrow Transplant Program CancerCare Manitoba. To date, there have been 1239 studies concluded and 901 ongoing trials taking place across several locations including Hackensack, New jersey."
Has Durvalumab been granted authorization by the FDA?
"There is limited evidence backing the safety and efficacy of Durvalumab, so it earned a rating of 1."
How many individuals have signed up for participation in this experiment?
"This particular investigation is not currently enrolling subjects. It was first announced on the 11th of January 2016, and its last update took place on the 4th of August 2021. If you are looking for alternative studies, 807 medical trials related to multiple myeloma and 901 surveys with regards to Durvalumab are presently recruiting test participants."
Share this study with friends
Copy Link
Messenger